Exploring the binding site of C-terminal Hsp90 inhibitors

Journal of Chemical Information and Modeling

Volumn 50, Issue 9, 2010, Pages 1522-1528

  Sgobba, Miriam ^a   Forestiero, Rosetta ^a   Degliesposti, Gianluca ^a   Rastelli, Giulio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMISTRY;

ANTICANCER DRUG DISCOVERY; C-TERMINAL DOMAINS; COMPUTATIONAL APPROACH; DIMER INTERFACE; HEAT SHOCK PROTEIN; N-TERMINAL DOMAINS;

CHEMICAL ENGINEERING;

HEAT SHOCK PROTEIN 90;

BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; LETTER; METABOLISM; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HSP90 HEAT-SHOCK PROTEINS; MODELS, MOLECULAR; PROTEIN CONFORMATION;

EID: 77957237356     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci1001857     Document Type: Article

References (44)

1. Pratt, W. B.; Toft, D. O. Steroid receptor interactions with heat shock protein and immunophilin chaperones Endocr. Rev. 1997, 18, 306-360
2. Blagosklonny, M. V.; Toretsky, J.; Bohen, S.; Neckers, L. Mutant conformation of p53 translated in vitro or in vivo requires functional Hsp90 Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8379-8383 (Pubitemid 26269566)
3. Söti, C.; Rácz, A.; Csermely, P. A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket J. Biol. Chem. 2002, 277, 7066-7075 (Pubitemid 34953095)
4. Marcu, M. G.; Chadli, A.; Bouhouche, I.; Catelli, M.; Neckers, L. M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone J. Biol. Chem. 2000, 275, 37181-37186 (Pubitemid 32002137)
5. Garnier, C.; Lafitte, D.; Tsvetkov, P. O.; Barbier, P.; Leclerc-Devin, J.; Millot, J.; Briand, C.; Makarov, A. A.; Catelli, M. G.; Peyrot, V. Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain J. Biol. Chem. 2002, 277, 12208-12214 (Pubitemid 34952787)
6. Allan, R. K.; Mok, D.; Ward, B. K.; Ratajczak, T. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization J. Biol. Chem. 2006, 281, 7161-7171 (Pubitemid 43847481)
7. Chakraborty, A.; Koldobskiy, M. A.; Sixt, K. M.; Juluri, K. R.; Mustafa, A. K.; Snowman, A. M.; van Rossum, D. B.; Patterson, R. L.; Snyder, S. H. Hsp90 regulates cell survival via inositol hexakisphosphate kinase-2 Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 1134-1139 (Pubitemid 351397019)
8. Marcu, M. G.; Schulte, T. W.; Neckers, L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins J. Natl. Cancer Inst. 2000, 92, 242-248 (Pubitemid 30099783)
9. Yu, X. M.; Shen, G.; Neckers, L.; Blake, H.; Holzbeierlein, J.; Cronk, B.; Blagg, B. S. J. Hsp90 inhibitors identified from a library of novobiocin analogues J. Am. Chem. Soc. 2005, 127, 12778-12779 (Pubitemid 41339147)
10. Burlison, J. A.; Neckers, L.; Smith, A. B.; Maxwell, A.; Blagg, B. S. J. Novobiocin: redesigning a DNA Gyrase inhibitor for selective inhibition of Hsp90 J. Am. Chem. Soc. 2006, 128, 15529-15536 (Pubitemid 44876029)
11. Burlison, J. A.; Blagg, B. S. J. Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery Org. Lett. 2006, 8, 4855-4858
12. Lin, J.; Perryman, A. L.; Schames, J. R.; McCammon, J. A. Computational drug design accommodating receptor flexibility: the relaxed complex scheme J. Am. Chem. Soc. 2002, 124, 5632-5633 (Pubitemid 34533490)
13. Lin, J.; Perryman, A. L.; Schames, J. R.; McCammon, J. A. The relaxed complex method: accommodating receptor flexibility for drug design with an improved scoring scheme Biopolymers 2003, 68, 47-62 (Pubitemid 36098307)
14. Mayer, M. P.; Prodromou, C.; Frydman, J. The Hsp90 mosaic: a picture emerges Nat. Struct. Mol. Biol. 2009, 16, 2-6
15. Shiau, A. K.; Harris, S. F.; Southworth, D. R.; Agard, D. A. Structural analysis of E. coli Hsp90 reveals dramatic nucleotide-dependent conformational rearrangements Cell 2006, 127, 329-340
16. Southworth, D. R.; Agard, D. A. Species-dependent ensembles of conserved conformational states define the Hsp90 chaperone ATPase cycle Mol. Cell 2008, 32, 631-640
17. Ali, M. M. U.; Roe, S. M.; Vaughan, C. K.; Meyer, P.; Panaretou, B.; Piper, P. W.; Prodromou, C.; Pearl, L. H. Crystal structure of an Hsp90-nucleotide-p23/sba1 closed chaperone complex Nature 2006, 440, 1013-1017
18. Sippl, M. J. Recognition of errors in three-dimensional structures of proteins Proteins 1993, 17, 355-362 (Pubitemid 23358545)
19. Eramian, D.; Shen, M.; Devos, D.; Melo, F.; Sali, A.; Marti-Renom, M. A. A composite score for predicting errors in protein structure models Protein Sci. 2006, 15, 1653-1666
20. Laskowski, R.; MacArthur, M.; Moss, D.; Thornton, J. Procheck: a program to check the stereochemical quality of protein structures J. Appl. Crystallogr. 1993, 26, 283-291
21. Bron, P.; Giudice, E.; Rolland, J.; Buey, R. M.; Barbier, P.; Díaz, J. F.; Peyrot, V.; Thomas, D.; Garnier, C. Apo-Hsp90 coexists in two open conformational states in solution Biol. Cell 2008, 100, 413-425 (Pubitemid 351943946)
22. Dollins, D. E.; Warren, J. J.; Immormino, R. M.; Gewirth, D. T. Structures of Grp94-nucleotide complexes reveal mechanistic differences between the Hsp90 chaperones Mol. Cell 2007, 28, 41-56
23. Krukenberg, K. A.; Förster, F.; Rice, L. M.; Sali, A.; Agard, D. A. Multiple conformations of E. coli Hsp90 in solution: insights into the conformational dynamics of Hsp90 Structure 2008, 16, 755-765 (Pubitemid 351615019)
24. Harris, R.; Olson, A. J.; Goodsell, D. S. Automated prediction of ligand-binding sites in proteins Proteins 2008, 70, 1506-1517 (Pubitemid 351304108)
25. Halgren, T. A. Identifying and characterizing binding sites and assessing druggability J. Chem. Inf. Model. 2009, 49, 377-389
26. Hetényi, C.; van der Spoel, D. Efficient docking of peptides to proteins without prior knowledge of the binding site Protein Sci. 2002, 11, 1729-1737 (Pubitemid 34663553)
27. Hetényi, C.; van der Spoel, D. Blind docking of drug-sized compounds to proteins with up to a thousand residues FEBS Lett. 2006, 580, 1447-1450 (Pubitemid 43222013)
28. Iorga, B.; Herlem, D.; Barré, E.; Guillou, C. Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the "blind docking" approach J. Mol. Model. 2006, 12, 366-372 (Pubitemid 43337207)
29. Vasko, R. C.; Rodriguez, R. A.; Cunningham, C. N.; Ardi, V. C.; Agard, D. A.; McAlpine, S. R. Mechanistic studies of sansalvamide A-amide: an allosteric modulator of Hsp90 ACS Med. Chem. Lett. 2010, 1, 4-8
30. Sgobba, M.; Degliesposti, G.; Ferrari, A. M.; Rastelli, G. Structural models and binding site prediction of the C-terminal domain of human Hsp90: a new target for anticancer drugs Chem. Biol. Drug Des. 2008, 71, 420-433 (Pubitemid 351519502)
31. Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. A semiempirical free energy force field with charge-based desolvation J. Comput. Chem. 2007, 28, 1145-1152
32. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749 (Pubitemid 38380917)
33. Ferrari, A. M.; Degliesposti, G.; Sgobba, M.; Rastelli, G. Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors Bioorg. Med. Chem. 2007, 15, 7865-7877 (Pubitemid 47575902)
34. Rastelli, G.; Degliesposti, G.; Del Rio, A.; Sgobba, M. Binding estimation after refinement, a new automated procedure for the refinement and rescoring of docked ligands in virtual screening Chem. Biol. Drug Des. 2009, 73, 283-286
35. Degliesposti, G.; Kasam, V.; Da Costa, A.; Kang, H.; Kim, N.; Kim, D.; Breton, V.; Kim, D.; Rastelli, G. Design and discovery of plasmepsin II inhibitors using an automated workflow on large-scale grids ChemMedChem 2009, 4, 1164-1173
36. Rastelli, G.; Del Rio, A.; Degliesposti, G.; Sgobba, M. Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA J. Comput. Chem. 2010, 31, 797-810
37. Verdonk, M. L.; Berdini, V.; Hartshorn, M. J.; Mooij, W. T. M.; Murray, C. W.; Taylor, R. D.; Watson, P. Virtual screening using protein-ligand docking: avoiding artificial enrichment J. Chem. Inf. Comput. Sci. 2004, 44, 793-806
38. Donnelly, A.; Blagg, B. S. J. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket Curr. Med. Chem. 2008, 15, 2702-2717
39. Retzlaff, M.; Stahl, M.; Eberl, H. C.; Lagleder, S.; Beck, J.; Kessler, H.; Buchner, J. Hsp90 is regulated by a switch point in the C-terminal domain EMBO Rep. 2009, 10, 1147-1153
40. Fang, L.; Ricketson, D.; Getubig, L.; Darimont, B. Unliganded and hormone-bound glucocorticoid receptors interact with distinct hydrophobic sites in the Hsp90 C-terminal domain Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 18487-18492 (Pubitemid 44913437)
41. Huang, N.; Shoichet, B. K.; Irwin, J. J. Benchmarking sets for molecular docking J. Med. Chem. 2006, 49, 6789-6801 (Pubitemid 44749746)
42. Burlison, J. A.; Avila, C.; Vielhauer, G.; Lubbers, D. J.; Holzbeierlein, J.; Blagg, B. S. J. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines J. Org. Chem. 2008, 73, 2130-2137 (Pubitemid 351497740)
43. Donnelly, A. C.; Mays, J. R.; Burlison, J. A.; Nelson, J. T.; Vielhauer, G.; Holzbeierlein, J.; Blagg, B. S. J. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity J. Org. Chem. 2008, 73, 8901-8920
44. Shelton, S. N.; Shawgo, M. E.; Matthews, S. B.; Lu, Y.; Donnelly, A. C.; Szabla, K.; Tanol, M.; Vielhauer, G. A.; Rajewski, R. A.; Matts, R. L.; Blagg, B. S. J.; Robertson, J. D. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells Mol. Pharmacol. 2009, 76, 1314-1322